Skip to main content

THE REGENERATION EFFECT
Home  Radiation Crises Antidote  Regenerative Lifestyles  Current Events  Education  Diseases FAQs  Essential Links  RE Survival  Who We Are   
Andras Konya MD PhD
Dana Flavin MD MS
Mitch Fleisher MD DHt
Mark Starr MD
MA Richardson DrPH
Merle Morgan MS OMD
Sharry Edwards MEd
Virginia Osborne ND RN
Steve Hines ND NE
Robert Ranger MA CCH
Dr John Apsley Exec Dir
IMREF
BWIMC

Dana F. Flavin, MD, MS

 

Founding Member of ICRM

 

Born in Chicago as the youngest child of Dr. and Mrs. Byron Flavin. Both parents studied Medicine and their excellent example of compassion and devotion to duty made a lasting impression on Dr. Flavin‟s life. Her continuous education in Science and Medicine has helped her to find and improve therapies for many diseases including Cancer, Autoimmune diseases such as Graves thyroiditis, rheumatoid arthritis and viral diseases. She received her first degree in Psychology and Chemistry from Loyola University in 1972 and then began graduate school in Pharmacology at Chicago Medical School. After 4 years and part I of her Medical Boards, she was appointed Science Assistant to the Associate Bureau Director for Toxicology at the Food and Drug Administration in Washington D.C.

 

During this time she researched the Molecular Biology of Cancer and Tumor Promotion investigating the application of Translational Medicine into potential therapies for cancer. She then was appointed Science Advisor to the President of the Nutrition Foundation and began graduate studies at Howard University in Nutrient Biochemistry under the Department of Nutrition. Several years later with summa cum Laude in Nutrition she moved to Germany and began her studies in Medicine for completion of her M.D. degree in Innsbruck, Austria, including years devoted to research.

 

Dr. Flavin was exposed to the traumas of illness early in her life when her father suffered a stoke leaving him partially paralyzed and without sufficient health insurance. She was 15 at the time. One year later, she herself suffered Epileptic seizures following a mild brain injury. She lost part of her vocabulary and alphabet recognition. The illness was treated with heavy medication for several years until it was found to be completely cured. In spite of all this she had straight A's in Biology in High School. At age 20, she was admitted into the hospital for a breast tumor. She was told they may have to perform a radical mastectomy. It was removed and fortunately found to be benign but one of a type that could, over time, have become malignant. Nine months later, she broke her neck in an automobile accident, leaving her in a hospital bed for 6 months. She was in a stryker frame with screws in her skull to stabilize her and she was unable to move . During this time she took additional reading courses for her degree. She had a Plexiglas table made so she could read lying down, since she was unable to walk or sit up until the vertebrae were later fused with an operation and then 12 weeks in a body cast. She was greatly influenced by the suffering in the Neurology department around her in Mercy Hospital for those six months and aware of her good fortune to be able to walk out on her own without paralysis. She realized the brain cancer patients she had met would not go home. That many in a coma would not be able to lead normal lives and that those paralyzed would not walk.

 

This is what started her devotion to help patients with illnesses and to relieve suffering and find cures.

 

Dr. Flavin recently began the Foundation for Collaborative Medicine and Research in Greenwich Connecticut to teach colleagues and patients what she has learned from around the world in areas of medicine and of nutrition and nutrients in fighting diseases. She is also helping find and develop new cutting edge therapies from around the world for cancer, diabetes, and many other diseases. Her successes include developing a new therapy for Mononucleosis that cures children in 24 hours, Published in the Journal of Orthomolecular Medicine, 2006, and a therapy for breast cancer patients that reverses brain metastases within 3 months, published in the Journal of Neuro-oncology, 2007. Recently she has reversed Non Hodgkin‟s lymphoma and medullary thyroid cancer using a new compound dichloroacetate, normally used for children with lactic acidosis. She is continuously searching for new therapies, both conventional and complementary, where there are limited treatments available. Presently she is researching out the increase in lactic acid and its changes in the cell in almost every disease, which is narrowing down diseases into systems, a discovery that has the potential to save millions of lives and reverse diseases.

 

 

"There is always a Treatment, we just have to find it" is her motto and she has devoted her life to help mankind in every way possible to relieve suffering, find cures and bring back hope to the hopeless and health to those who were dying.

 

Curriculum Vitae

EDUCATION:

 

Innsbruck, Austria

LeopoldFranzens University: Doctor of Medicine 1999

 

Medicine/Biochemical Pharmacology1999

 

Munich, Germany

 

TechnicalUniversity Medical SchoolDoctor of Medicine 1996

 

Washington, D. C., USA

 

Howard University,MS Nutrition/Biochemistry, summa cum laude1986

 

GeorgetownUniversity Medical SchoolGross Anatomy,Honors1975

 

Chicago, IL, USA

 

ChicagoUniversity, Finch University of Health SciencesPharmacology, Ph.D. Candidate1975

 

LoyolaUniversityBS Psychology/Chemistry1972

 

Medical Training Bad Heilbrunn,Germany

 

Internal Medicine/OncologyLeonardis Oncology Klinik 2000-2004

 

Berg, Germany

 

SurgeryStarnberg Community Hospital1998

 

General Medicine Dr. Reinhard Luyken Private Practice 1993

 

Internal/Intensive MedicineArgirov Klinik1993

 

PsychiatryRottmannshoehe Heckscher Klinik1992

 

PROFESSIONAL POSITIONS:

 

The Foundation for Collaborative Medicine and ResearchWashington, D. C., USA2001-present

 

Founding Director

 

Flavin Pharmaceuticals, IncGreenwich, CT2008

 

Chairman

 

Dancour, LLCGreenwich, CT2009

 

Chairman

IMRAC, Haus BurkstettenBerg, Germany1999

 

International Medical Research & Consulting

 

Bristol Myers SquibbBrussels, Belgium1999Oncology/Advisor

 

Novartis Consumer Health (Ciba-Geigy)Nyon, Switzerland1997 - 1998

 

Medical/ Scientific Advisor

 

New Drug research and Development

 

BASFLudwigshafen, Germany1987 - 1989

 

Science Consultant

 

Vitamins and cancer

 

The Nutrition Foundation Washington, D. C. 1982 - 1985

 

Science Advisor to the President

 

Food and Drug AdministrationWashington, D. C.1979 - 1982

 

Science Assistant to the Associate Bureau Director for Toxicology1980 - 1982

 

Pharmacologist1979 - 1980

 

Warren - Teed PharmaceuticalsColumbus, Ohio 1978 - 1979

 

Sales and Marketing Representative

 

Consultant , Science/ PharmacologyWashington, D. C.1975 - 1978

 

Morris And Ward Consultants1977 - 1978

 

SoutheastCommunity Hospital1975 - 1977

 

PATENTS:

 

U. S., Patent Application Viral Hepatitis Treatment. 531,3001980

 

Germany, Patent Registration Combination Preparation for Viral diseases. 103 40 845.22004

 

Rheumabehandlung/Arthritis Treatment.Patent Pending2004

 

LANGUAGES: Fluent: English, German, Spanish

 

COMPANY CONSULTATION AND PRESENTATIONS:

 

BASFNutrients and Cancer Prevention

 

NovartisViral toxicities and Therapies

 

Roche PharmaceuticalsNew Cancer Therapy Development

 

BionoricaPhytopharmacology and Disease Treatment

 

Bristol Myer SquibbTranslational Oncology

 

PfizerMechanism or Cancer Growth and Immune Suppression

 

TARGETED THERAPIES:

 

·Autoimmune Disease Therapy with Natural Substances (Book). (In Revisal, copyright, 2000)

 

·Medical Treatments and Support Therapies Developed:

 

·Epstein Barr Virus, Hepatosplenomegalies cured in 24 - 28 hours.

 

·HBV, Inhibition of liver toxicity,

 

·HIV, Increase in T - cells and general health.

 

·Asthma, total elimination of steroid needs.

 

·Colitis Ulcerosa, Elimination of steroids and all conventional medicines.

 

·Rheumatoid Arthritis, total elimination of steroids and other conventional medicines.

 

·Multiple Sclerosis. Elimination of relapses, steroid needs, and conventional medicines in 99% of cases.

 

·Lupus Erythematosus, Elimination of steroids, and most conventional medicine.

 

·Morbus Crohn, Elimination of steroids and conventional medicines in 85% of cases.

 

·Graves Disease: reduced antibodies (TRAb) and Thyroid values to normal in 3 weeks.

 

·Hashimotos: Reduced antibodies 90% in 4 weeks (TPO). No more symptoms of fatigue etc.

 

·Cancer therapies:

 

·Cervix cancer cured in 6 months using all natural substances.

 

·Ovarian carcinoma with plura metasases totally reduced in 3 months, accompanying therapy carboplatin and Cyclophosphamide. No side effects from chemo.

 

·Colon cancer (adenocarcinoma) total remission, liver lung and lymph metastases gone in 3 months, CT clear, accompanying therapy 5FU. No side effects from chemo

 

·Breast cancer with 30 brain metastases totally reduced in 10 weeks, still in remission over three years.

 

·Acute myelogenous leukemia in total remission with chemotherapy, no side effects from chemo

 

·Non Hodgkins Lymphoma three month reversal with natural therapies.

 

ABSTRACTS:

 

I.D. F. Flavin. Tryptamine Receptors in the Frog Heart Ventricle. Sigma Xi, 1973

 

II.W. A. Pedemonte, D. F. Flavin, H. C. Sabelli. Indolacetate Activation of Tryptamine Receptors in the Frog Heart. The Pharmacologist 15 (2), 135, 1973

 

III.D. F: Flavin. Behavioral and Electrophysiological Effects of Phenylethanolamine - A Putative Neurotransmitter. Sigma Xi, 1974.

 

IV.D. F. Flavin - Koenig. What Do We About Orthomolecular Therapy? 34. Medicine week Conference. Baden - Baden, Germany, 2000.

 

PRESENTATIONS:

 

·Indolacetate activation of Tryptamine Receptors in the Frog Heart.American Society for Pharmacology and Experimental Therapeutics. Eastern Michigan University. Ypsilanti, Michigan, 1973.

 

·Behavioral and Electrophysiological effects of Phenylethanolamine, a Putative Neurotransmitter. Sigma Xi, Chicago Medical School. Chicago, Illinois, 1974.

 

·The Effects of Pargyline on the Electrical Activity of the Membrane. George Washington University. Washington, D. C., 1980.

 

·Your Body's Future. Nutrition and Health, World Future Society, Washington, D.C. Chapter, 1981.

 

·Multiple Modalities in Tumor Prevention and Treatment. Cancer Conference. University of Arizona. Tucson, Arizona, 1982.

 

·Cancer Prevention. Hillside Hospital, Livingston Clinic. San Diego, California, 1982.

 

·Nutritional Alterations in the Biochemistry of Tumor Promotion. F.D.A. Washington, D.C., 1982.

 

·Nutritional Effects in Tumor Promotion. Institut Suisse de Experimentale sur le Cancer, ISREC. Epalinges sur Lausanne, Switzerland, 1983.

 

·Nutrition and Cancer. American International Hospital. Zion, Illinois, 1983.

 

·Nutritional Factors that Inhibit Tumor Promotion. North Carolina State University. Raleigh, North Carolina, 1984.

 

·Nutrients in Cancer Prevention. Instituto Superiore di Sanita. Rome, Italy. 1984.

 

·Nutrients and Oxygen Radical Interactions in Tumor Promotion. National Institute of Health National Cancer Institute. Bethesda, Maryland, 1985.

 

·Molecular Changes in Tumor Promotion and Relationship to Oxygen radicals.Gesellschaft fr Strahlen - und Umweltforschung (Radiation Research Center). Munich, Germany, 1987.

 

·Nutritional Prevention in Cancer. National Congress on Nutrition and Cancer. Trieste, Italy, 1988.

 

·Antioxidants in Cancer Prevention. International Association of Vitamins and Nutritional Oncology. Charleston, South Carolina, USA, 1989.

 

·Oxygen Radicals in Neurological Toxicity. Neurology Disease Conference, All India Institute for Medical Research. New Delhi, India, 1991.

 

·Oxygen Radicals in Liver Disease. Oxygen Radical Conference, Semmelweis University. Budapest, Hungary, 1993.

 

·New Treatments in Hepatitis, Technical University Medical School/Glaxo Wellcome. Munich, Germany, 1994.

 

·Xanthine Oxidase and Nitric Oxide Synthase in Viral Disease: Reversal of Hepatosplenomegaly in EBV Infected Children in 24 - 48 Hours. LMU/ GroBhadern Hospital, MED POLY II, 1994.

 

·Immune Modulation in Viral Hepatitis Treatments, New Drug Development. ESSEX Pharm. Munich, Germany, 1995.

 

·New Viral Treatments. Developments for Future Pharmacological Applications. Novartis/Ciba - Geigy. Nyon, Switzerland, 1997.

 

·The Role of Nitric Oxide Synthase in Disease and Toxicity. Boehringer Mannheim/Hoffman - La Roche. Penzberg, Germany, 1997.

 

·New Concepts in Drug Development: The Mechanism of Natural Inhibitors of Viral Replication and Toxicity. Bionorica, Arzneimittel, Neumarkt, Germany, 1999

 

·What Do We Know About Orthomolecular Therapy, Cancer: Replication & Immune Suppression Mechanisms of Nutrient Supplements, 34 Medicine Week Conference, Baden - Baden, Germany, 2000.

 

·Integrated Therapy in Cancer Treatment, Cross Talking at the Cellular Level. Centro Prevenzione Salute. Livorno, Italy, February 16, 2002.

 

·The Application of Natural Substances in Tumor Therapy: The Oncology Patient. Community Hospital at Hall, in Tirol (Sponsor). Hilton Hotel, Innsbruck, Austria, Nov 9, 2002.

 

·Integrated Therapy in Cancer Treatment, Cross Talking at the Cellular level. Centro Prevenzione in Oncologie. Giornata Internazionale di Studio, Attualita E Prospettive. Rome, Italy, Nov 13, 2003.

 

·Health Forum Conference, Nutrients and Nutrition in Cancer Prevention and Treatment.Hilton Hotel, Munich, Germany, June 3, 2004.

 

·Integrative Medizin in der Onkologie, Leonardis Klinik, Bad Heilbrunn Germany: "Increased Response in Cancer Therapy through Molecular biology", October 16, 2004.

 

·Prevention instead of Intervention, Leonardis Klinik, Bad Heilbrunn, Germany

 

  • "Multifactoral Preventive Measures against Cancer", June 25, 2005.

 

·Nutritients in Cancer Therapy. C.A.R.E. Meeting, Methodist church. Ridgewood, New Jersey, November 10, 2005.

 

·Understanding Cancer, International Research in Therapy. C.AR.E Meeting, December 8, 2005.

 

·Preventing Cancer, Cos Cob Library, Cos Cob CT, April 2007.

 

·Anti Cancer and Anti Aging, Greenwich Library, Greenwich CT.May, 2007

 

PUBLICATIONS:

 

       1.Differential Effects of Two Putative Neuromodulators, 2 - Phenylethylamine and Phenylethanolamine. H. C. Sabelli, A.J. Vasquez, and D. F. Flavin. The Society of Neuroscience, 1974.

 

2.Behavioral and Electrophysiological Effects of Phenylethanolamine and 2 - Phenylethylamine. H.C. Sabelli, A.J. Vasquez, and D. F. Flavin. Psychopharmacologia, 42 (2), 117 - 125, 1975.

 

3.Cimetidine, an Antihistaminic. D. F. Flavin. Monograph for the American Society of Hospital Pharmacists, January, 1978.

 

4.Neurobehavioral Test Outline for Drug and/or Chemical Toxicity Studies and Evaluations. D. F. Flavin. Division of Toxicology, F.D.A., February, 1979.

 

5.Carcinogens and Steroid Receptors. D. F. Flavin. Harvard Magazine, Letter, 1981.

 

6.The Effects of Soybean Trypsin Inhibitor on the Pancreas of Animals and Man. Review. D. F. Flavin. Veterinary and Human Toxicology, 24, 25 - 28, 1982.

 

7.Nutritional factors with the Potential to Inhibit Critical Pathways of Tumor Promotion. D. F. Flavin, A. C. Kolbye, Jr. in Modulation and Mediation of Cancer by Vitamins (eds., F. L. Meyskens, K. N. Prasad) pp. 24 - 32, Karger, Basel, Switzerland, 1983.

 

8.Generalized Cellular Toxicity in Toxic Hyperplasia and Tumor Promotion. D. F. Flavin and C. J. Carr. Appendix C, Response By the Nutrition Foundation, Inc. to the Office Science and Technology Policy: Chemical Carcinogens, Notice of Review of the Science and its Associated Principles, Federal Register Draft Document, May 22, 1984.

 

9.Toxicity, Tumor Promotion and Carcinogenesis in Relation to Excessive Dosage. D. F. Flavin, Regulatory Toxicology and Pharmacology, 4, 372 - 379, 1984.

 

10.Cancerous Esoterous. D. F. Flavin, in Advances in Free Radicals, Biology and Medicine, (ed. W. A. Pryor) Academic Press, Vol. 2, 445 - 451, 1986.

 

11.The Role of Putative Chemopreventive Nutrients, Retinoids, Tocopherols, Ascorbic Acid, and Selenium, in Cancer Induction. D. F. Flavin, (summa cum Laude) Masters Thesis, Howard University, Washington, D. C., 1986.

 

12.A Common Enemy (Peroxynitrite). D. F. Flavin - Koenig, The New Zealand Medical Journal, Vol. 108, pg. 89, 1995.

 

13.The reversal of Epstein Barr Virus Induced Hepatosplenomegaly in 24 Hours with Inhibitors of Xanthine Oxidase and Nitric Oxide Synthase. D. F. Flavin - Koenig and W. Tschollar, The New Zealand Medical Journal, 22 March, pg. 106 - 107, 1996.

 

14.What Do We Know About OrthomolecularMedicine?: Cancer: Replication and Immune suppression, Mechanisms of Nutrient Supplements. 34. Medizinische Woche, 28. October to 3 November, (Karl F. Haug Verlag, in MVH Medizinverlage Heidelberg Gmbh & Co. KG,) Manuscript accepted. 2000/2001.

 

15.Reversing Splenomegalies in Epstein Barr Virus Infected Children: Mechanisms of toxicity in Viral diseases, Dana F. Flavin, The Journal of Orthomolecular Medicine, Second Quarter, 21:2, Pg 95-101, 2006.

 

16.A Lipoxygenase Inhibitor in Breast Cancer Brain Metastases, D.F.Flavin, J Neurooncology, 82:91-93, 2007.

 

POSTERS:

 

a)The Reversal of Hepatosplenomegaly in EBV infected children

 

b)Gesellschaft fur Strahlen Forschung , Dr. med Dana F. Flavin - Knig

 

c)Neuherberg ,Germany, 1996.

 

d)Annual Conference Effect of Lactoferrin in Cancer and G.I. Diseases: Dr. D. F. Flavin - Koenig and Massimo Bonucci. Capri, Italy, May 2003.

 

RADIO INTERVIEWS:

 

WBAI New York. February 2005, July 2005, November 2005, December 2005.

 

Television Interviews: CBN News, The Toxicity of Corn Syrup, Feb 4, 2009.

 

AWARDS: Women of Innovation in Science and Medicine, Connecticut Technology Council, January 30, 2008